Reslizumab (original) (raw)
Reslizumab (Handelsname: Cinqaero von Teva Pharmaceutical Industries) ist ein humanisierter monoklonaler Antikörper zur Behandlung von Asthma bronchiale. Reslizumab bindet spezifisch an das humane Interleukin-5 (IL-5) und stört die Bindung von IL-5 an dessen Zelloberflächenrezeptor.
| Property | Value |
|---|---|
| dbo:abstract | Reslizumab (Handelsname: Cinqaero von Teva Pharmaceutical Industries) ist ein humanisierter monoklonaler Antikörper zur Behandlung von Asthma bronchiale. Reslizumab bindet spezifisch an das humane Interleukin-5 (IL-5) und stört die Bindung von IL-5 an dessen Zelloberflächenrezeptor. (de) Le reslizumab, commercialisé sous le nom de Cinqaero, est un anticorps monoclonal humanisé (IgG4, κ) dirigé contre l'interleukine 5 (IL-5) humaine. Il se lie spécifiquement à l'IL-5 et interfère avec la liaison de l'IL-5 à son récepteur de surface cellulaire et bloque ainsi sa fonction biologique, ce qui a pour conséquence de réduire la survie et l'activité des éosinophiles. (fr) Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions. The FDA approved reslizumab (US trade name Cinqair) for use with other asthma medicines for the maintenance treatment of severe asthma in patients aged 18 years and older on 23 March 2016. Cinqair is approved for patients who have a history of severe asthma attacks (exacerbations) despite receiving their current asthma medicines. The European Medicines Agency recommended the granting of a marketing authorisation for reslizumab (EU trade name Cinqaero) intended as add-on treatment in adult patients with severe eosinophilic asthma on 23 June 2016. Reslizumab is supplied as a refrigerated, sterile, single-use, preservative-free solution for intravenous infusion. The reslizumab solution is a slightly hazy/opalescent, slightly yellow liquid and is supplied as 100 mg in a 10 mL glass vial. Each single-use vial of reslizumab is formulated as 10 mg/mL reslizumab in an aqueous solution containing 2.45 mg/mL sodium acetate trihydrate, 0.12 mg/mL glacial acetic acid, and 70 mg/mL sucrose, with a pH of 5.5. (en) Reslizumab (łac. reslizumabum) – humanizowane przeciwciało monoklonalne klasy IgG4/к, wytwarzane metodą inżynierii genetycznej w komórkach szpiczaka mysiego (NS0), stosowane w leczeniu astmy oskrzelowej. (pl) Реслизумаб — лекарственный препарат, моноклональное антитело для лечения бронхиальной астмы. Одобрен для применения: ЕС, США (2016) 23 марта 2016 года FDA одобрило реслизумаб для использования с другими лекарствами от астмы для поддерживающего лечения тяжелой астмы у пациентов в возрасте 18 лет и старше. Реслизумаб одобрен для пациентов, у которых в анамнезе имеются тяжелые приступы астмы, несмотря на приём текущих лекарств от астмы. 23 июня 2016 года Европейское агентство лекарственных средств рекомендовало выдать разрешение на применение реслизумаба, предназначенного для дополнительного лечения взрослых пациентов с тяжелой эозинофильной астмой. (ru) |
| dbo:alternativeName | Cinqair (US), Cinqaero (EU) (en) |
| dbo:casNumber | 241473-69-8 |
| dbo:drugbank | DB06602 |
| dbo:fdaUniiCode | 35A26E427H |
| dbo:kegg | D08985 |
| dbo:wikiPageExternalLink | https://druginfo.nlm.nih.gov/drugportal/name/reslizumab |
| dbo:wikiPageID | 9134258 (xsd:integer) |
| dbo:wikiPageLength | 12012 (xsd:nonNegativeInteger) |
| dbo:wikiPageRevisionID | 1063130779 (xsd:integer) |
| dbo:wikiPageWikiLink | dbc:Antiasthmatic_drugs dbr:Schering-Plough dbr:Peptide dbr:Cytokine dbr:Interleukin_5 dbr:Proteolysis dbr:Eosinophil dbr:Malignancy dbr:Sucrose dbr:Clinical_trial dbr:Cephalon dbr:Amino_acid dbr:European_Medicines_Agency dbr:FDA dbr:Teva_Pharmaceuticals dbc:Monoclonal_antibodies dbr:Placebo dbr:Sputum dbr:Microlitre dbr:Volume_of_distribution dbr:Pharmacokinetics dbr:Exacerbation dbr:Myalgia dbr:Humanized_monoclonal_antibody dbr:Intravenous dbr:Eosinophilic_asthma dbr:Oropharyngeal dbr:Anaphylactic_reactions dbr:Creatine_phosphokinase dbr:Picomolar dbr:Ception_Therapeutics |
| dbp:atcPrefix | R03 (en) |
| dbp:atcSuffix | DX08 (en) |
| dbp:casNumber | 241473 (xsd:integer) |
| dbp:chemspiderid | none (en) |
| dbp:dailymedid | Reslizumab (en) |
| dbp:drugbank | DB06602 (en) |
| dbp:eliminationHalfLife | 2073600.0 (dbd:second) |
| dbp:kegg | D08985 (en) |
| dbp:legalAu | S4 (en) |
| dbp:legalEu | Rx-only (en) |
| dbp:legalUs | Rx-only (en) |
| dbp:licenceEu | yes (en) |
| dbp:licenceUs | Reslizumab (en) |
| dbp:mabType | mab (en) |
| dbp:metabolism | dbr:Proteolysis |
| dbp:routesOfAdministration | dbr:Intravenous |
| dbp:source | zu/a (en) |
| dbp:target | dbr:Interleukin_5 |
| dbp:tradename | Cinqair , Cinqaero (en) |
| dbp:type | mab (en) |
| dbp:unii | 35 (xsd:integer) |
| dbp:verifiedfields | changed (en) |
| dbp:verifiedrevid | 464381171 (xsd:integer) |
| dbp:watchedfields | changed (en) |
| dbp:wikiPageUsesTemplate | dbt:Cite_web dbt:Drugbox dbt:Empty_section dbt:Portal_bar dbt:Reflist dbt:Short_description dbt:Cascite dbt:Chemspidercite dbt:Drugbankcite dbt:Fdacite dbt:Keggcite dbt:Interleukin_receptor_modulators dbt:Drugs.com dbt:Monoclonals_for_immune_system dbt:Immunosuppressants |
| dct:subject | dbc:Antiasthmatic_drugs dbc:Monoclonal_antibodies |
| gold:hypernym | dbr:Antibody |
| rdf:type | owl:Thing dul:ChemicalObject dbo:ChemicalSubstance wikidata:Q8386 dbo:MonoclonalAntibody yago:WikicatMonoclonalAntibodies yago:Abstraction100002137 yago:Antibody115027189 yago:Chemical114806838 yago:Compound114818238 yago:Macromolecule114944888 yago:Material114580897 yago:Matter100020827 yago:Molecule114682133 yago:MonoclonalAntibody115029781 yago:OrganicCompound114727670 yago:Part113809207 yago:PhysicalEntity100001930 yago:Protein114728724 yago:Relation100031921 dbo:Drug yago:Substance100019613 yago:Thing100002452 yago:Unit109465459 |
| rdfs:comment | Reslizumab (Handelsname: Cinqaero von Teva Pharmaceutical Industries) ist ein humanisierter monoklonaler Antikörper zur Behandlung von Asthma bronchiale. Reslizumab bindet spezifisch an das humane Interleukin-5 (IL-5) und stört die Bindung von IL-5 an dessen Zelloberflächenrezeptor. (de) Le reslizumab, commercialisé sous le nom de Cinqaero, est un anticorps monoclonal humanisé (IgG4, κ) dirigé contre l'interleukine 5 (IL-5) humaine. Il se lie spécifiquement à l'IL-5 et interfère avec la liaison de l'IL-5 à son récepteur de surface cellulaire et bloque ainsi sa fonction biologique, ce qui a pour conséquence de réduire la survie et l'activité des éosinophiles. (fr) Reslizumab (łac. reslizumabum) – humanizowane przeciwciało monoklonalne klasy IgG4/к, wytwarzane metodą inżynierii genetycznej w komórkach szpiczaka mysiego (NS0), stosowane w leczeniu astmy oskrzelowej. (pl) Reslizumab is a humanized monoclonal antibody against human interleukin-5 (IL-5). Reslizumab binds specifically to IL-5, a key cytokine responsible for the differentiation, maturation, recruitment and activation of human eosinophils. By binding to human IL-5, it blocks its biological function; consequently survival and activity of eosinophils are reduced. The benefits with reslizumab are its ability to reduce the exacerbation rate and improve lung function and asthma-related quality of life in patients with severe eosinophilic asthma (with blood eosinophil count ≥ 400 cells/μL) and with at least one previous asthma exacerbation in the preceding year. The most common side effects are increased blood creatine phosphokinase, myalgia and anaphylactic reactions. (en) Реслизумаб — лекарственный препарат, моноклональное антитело для лечения бронхиальной астмы. Одобрен для применения: ЕС, США (2016) 23 марта 2016 года FDA одобрило реслизумаб для использования с другими лекарствами от астмы для поддерживающего лечения тяжелой астмы у пациентов в возрасте 18 лет и старше. Реслизумаб одобрен для пациентов, у которых в анамнезе имеются тяжелые приступы астмы, несмотря на приём текущих лекарств от астмы. (ru) |
| rdfs:label | Reslizumab (de) Reslizumab (fr) Reslizumab (en) Reslizumab (pl) Реслизумаб (ru) |
| owl:sameAs | freebase:Reslizumab yago-res:Reslizumab wikidata:Reslizumab dbpedia-de:Reslizumab dbpedia-fr:Reslizumab dbpedia-pl:Reslizumab dbpedia-ru:Reslizumab dbpedia-vi:Reslizumab https://global.dbpedia.org/id/4tdrP |
| prov:wasDerivedFrom | wikipedia-en:Reslizumab?oldid=1063130779&ns=0 |
| foaf:isPrimaryTopicOf | wikipedia-en:Reslizumab |
| is dbo:wikiPageRedirects of | dbr:Cinqaero dbr:Cinqair dbr:Cinquil |
| is dbo:wikiPageWikiLink of | dbr:Interleukin-5_receptor dbr:Interleukin_5 dbr:Interleukin_5_receptor_alpha_subunit dbr:Eosinophil dbr:Monoclonal_antibody_therapy dbr:Cinqaero dbr:Cinqair dbr:Cinquil dbr:Asthma dbr:ATC_code_R03 dbr:List_of_therapeutic_monoclonal_antibodies dbr:Lymphocyte-variant_hypereosinophilia dbr:List_of_drugs:_Re dbr:Type_2_inflammation |
| is foaf:primaryTopic of | wikipedia-en:Reslizumab |